podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. Medizin - Open Access LMU - Teil 14/22 Podcast
  4. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas
Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas

Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas

Medizin - Open Access LMU - Teil 14/22 vor 20 Jahren
Zu Sammlung hinzufügen

Du hast noch keine Sammlungen.
Herunterladen (rechte Maustaste) Teilen Fundstellen Kommentare
0:00
0:00
Background: Prognosis of patients with metastatic soft tissue
sarcomas (MSTS) is poor even after response to doxorubicin-based
chemotherapy. We report phase II data of highdose chemotherapy and
peripheral blood stem cell (PBSC) rescue in patients with MSTS
responding to AI-G chemotherapy. Patients and Methods: From 1997 to
2002, 55 patients with MSTS were prospectively treated with 4
cycles of AI-G (doxorubicin 75 mg/m(2), ifosfamide 6 g/m(2) with
G-CSF support). Responders received 2 further cycles of AI-G with
collection of PBSCs. High-dose chemotherapy consisted of ifosfamide
12 g/m(2), carboplatin 1.2 g/m(2) and etoposide 1.2 g/m(2) (HD-ICE)
followed by reinfusion of PBSCs. Results: Twenty-one of 55 patients
(38%) were assessed as responders (3 complete response, 18 partial
response). All but 2 patients refusing treatment received high-dose
chemotherapy with PBSC rescue leading to grade IV hematologic
toxicity without severe infections in all patients. No toxic death
occurred. After a median follow-up time of 30 months, the median
progression-free time was 12 months and survival time was 22 months
for the entire group. By intent-totreat analysis the probability of
5-year progression-free survival was significantly higher for
patients allocated to HD-ICE compared to patients receiving
second-line chemotherapy after failure of AI-G (14 vs. 3%; p =
0.003). The estimated 5-year overall survival between the 2 groups
was different (27% vs. not reached) but did not reach significance
(p = 0.08). Conclusion: HD-ICE is feasible and promising in
patients with chemosensitive MSTS. A randomized phase III trial is
warranted to further define the role of HD-ICE as consolidation
treatment in these patients.

Weitere Episoden

External quality assessment of urinary methylmalonic acid quantification - results of a pilot study

External quality assessment of urinary methylmalonic acid quantification - results of a pilot study

vor 19 Jahren
Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell turnours

Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell turnours

vor 19 Jahren
Free serum cortisol: quantification applying equilibrium dialysis or ultrafiltration and an automated immunoassay system

Free serum cortisol: quantification applying equilibrium dialysis or ultrafiltration and an automated immunoassay system

vor 19 Jahren
Die Biegestabprothese: ein experimenteller Ansatz zur metaphysären Hüftendoprothetik

Die Biegestabprothese: ein experimenteller Ansatz zur metaphysären Hüftendoprothetik

vor 19 Jahren
ASCO 2007: What remains important for breast cancer systemic therapy in the routine setting?

ASCO 2007: What remains important for breast cancer systemic therapy in the routine setting?

vor 19 Jahren
Alle Episoden anzeigen
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Episode melden

„Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz